DE602005013671D1 - (r/s) rifamycin-derivate, ihre herstellung und pharmazeutische zusammensetzungen - Google Patents

(r/s) rifamycin-derivate, ihre herstellung und pharmazeutische zusammensetzungen

Info

Publication number
DE602005013671D1
DE602005013671D1 DE602005013671T DE602005013671T DE602005013671D1 DE 602005013671 D1 DE602005013671 D1 DE 602005013671D1 DE 602005013671 T DE602005013671 T DE 602005013671T DE 602005013671 T DE602005013671 T DE 602005013671T DE 602005013671 D1 DE602005013671 D1 DE 602005013671D1
Authority
DE
Germany
Prior art keywords
sub
rifamycin derivatives
preparation
humans
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005013671T
Other languages
English (en)
Inventor
Charles Z Ding
Zhenkun Ma
Jing Li
Susan Harran
Yong He
Keith P Minor
In Ho Kim
Jamie Carol Longgood
Yafei Jin
Keith D Combrink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CUMBRE IP VENTURES L.P., DALLAS, TEX., US
Original Assignee
CUMBRE PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CUMBRE PHARMACEUTICALS Inc filed Critical CUMBRE PHARMACEUTICALS Inc
Publication of DE602005013671D1 publication Critical patent/DE602005013671D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DE602005013671T 2004-07-22 2005-07-21 (r/s) rifamycin-derivate, ihre herstellung und pharmazeutische zusammensetzungen Active DE602005013671D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59019004P 2004-07-22 2004-07-22
PCT/US2005/025924 WO2006012443A1 (en) 2004-07-22 2005-07-21 (r/s) rifamycin derivatives, their preparation and pharmaceutical compositions

Publications (1)

Publication Number Publication Date
DE602005013671D1 true DE602005013671D1 (de) 2009-05-14

Family

ID=35355764

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005013671T Active DE602005013671D1 (de) 2004-07-22 2005-07-21 (r/s) rifamycin-derivate, ihre herstellung und pharmazeutische zusammensetzungen

Country Status (11)

Country Link
US (2) US7226931B2 (de)
EP (2) EP1781670A1 (de)
JP (2) JP5236944B2 (de)
CN (2) CN101031572B (de)
AT (1) ATE427311T1 (de)
AU (1) AU2005267054B2 (de)
CA (2) CA2574307A1 (de)
DE (1) DE602005013671D1 (de)
HK (1) HK1102808A1 (de)
NZ (1) NZ565002A (de)
WO (2) WO2006012443A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
WO2005009364A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2006528189A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質産物、その使用法および製剤
JP2006528190A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
JP2007502296A (ja) 2003-08-11 2007-02-08 アドバンシス ファーマスーティカル コーポレイション ロバストペレット
EP1653924A4 (de) 2003-08-12 2009-09-09 Middlebrook Pharmaceuticals In Antibiotisches produkt, seine verwendung und formulierung
CA2535780A1 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005027877A1 (en) * 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005056526A1 (ja) 2003-12-12 2005-06-23 Daiichi Pharmaceutical Co., Ltd. 光学活性なシクロプロピルアミン誘導体の製造中間体およびその製造法
AU2005269981A1 (en) * 2004-07-02 2006-02-09 Bonck, John A Tablet for pulsed delivery
GB0505909D0 (en) * 2005-03-23 2005-04-27 Univ Leeds Formulations
JP5368092B2 (ja) 2005-08-11 2013-12-18 ターガンタ セラピュティクス，インコーポレイティド ホスホン化リファマイシン類および骨と関節感染の予防と治療のためのその投与法
WO2007021683A2 (en) 2005-08-15 2007-02-22 Janssen Pharmaceutica N.V. Human cell clones useful for functional analyses of the biological activity of an endogeneous urotensin ii receptor and uses thereof
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
TWI454262B (zh) 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
WO2009064792A1 (en) * 2007-11-16 2009-05-22 Cumbre Pharmaceuticals Inc. Quinolone carboxylic acid-substituted rifamycin derivatives
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
BRPI0908864A2 (pt) 2008-02-25 2018-09-18 Salix Pharmaceuticals Ltd formas da rifaximina e usos das mesmas
KR20100122508A (ko) * 2008-03-05 2010-11-22 타가셉트 인코포레이티드 디아자비시클로알칸의 니코틴 아세틸콜린 수용체 서브-타입 선택성 아미드
US8278313B2 (en) * 2008-03-11 2012-10-02 Abbott Laboratories Macrocyclic spiro pyrimidine derivatives
EP2324041A4 (de) 2008-08-13 2012-06-13 Targanta Therapeutics Corp Phosphonierte rifamycine und ihre anwendung zur vermeidung und behandlung von knochen- und gelenkinfektionen
CN101875658B (zh) * 2009-04-28 2013-01-09 上海药明康德新药开发有限公司 3-羰基-2,8-二氮杂螺[4.5] 癸烷-8-羧酸叔丁酯的制备方法
UA107812C2 (en) 2009-10-23 2015-02-25 Janssen Pharmaceutica Nv Oktahidropirolo disubstituted [3,4-c] pyrrole receptors as orexin modulators
CA2801074A1 (en) 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
EP2882435B8 (de) * 2012-08-13 2024-01-03 Adipharm Ead Pharmazeutische Formulierungen mit 3-(4-Cinnamyl-L-piperazinyl)aminoderivaten von 3-Formylrifamycin S
EP2895169A4 (de) * 2012-09-12 2016-02-24 Salix Pharmaceuticals Inc Verfahren zur verabreichung von rifaximin ohne erzeugung einer antibiotikaresistenz
CN103709177B (zh) * 2013-12-20 2016-02-24 武汉工程大学 利福霉素类沃尼妙林杂合抗生素及其制备方法
CN104710439B (zh) * 2015-03-06 2017-11-07 丹诺医药(苏州）有限公司 一种利福霉素‑喹嗪酮双靶标分子的晶型i及其制备方法
CN104628745B (zh) * 2015-03-06 2017-03-08 丹诺医药(苏州）有限公司 一种利福霉素‑喹嗪酮双靶标分子的富马酸盐及其制备方法
MD3426251T2 (ro) 2016-03-10 2022-09-30 Janssen Pharmaceutica Nv Metode de tratament al depresiei utilizând antagoniști ai receptorului orexină-2
CN105879009A (zh) * 2016-04-18 2016-08-24 丹诺医药(苏州）有限公司 一种用于治疗革兰氏阴性菌感染的抗菌药物组合物
RU2018146946A (ru) * 2016-06-08 2020-07-10 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Химические соединения
CN106822125A (zh) * 2017-02-28 2017-06-13 丹诺医药(苏州）有限公司 一种利福霉素‑喹嗪酮双靶标分子的新用途
CN106902116B (zh) * 2017-02-28 2021-03-23 丹诺医药(苏州）有限公司 一种利福霉素-喹嗪酮双靶标分子的应用
CN109251258B (zh) * 2017-07-13 2021-06-01 中国石油天然气股份有限公司 宽分布聚丙烯催化组分、组分制备方法及其催化剂
CN110944999A (zh) * 2017-08-01 2020-03-31 勃林格殷格翰国际有限公司 中间体化合物和方法
CN108310393A (zh) * 2018-02-12 2018-07-24 丹诺医药(苏州）有限公司 一种利福霉素-喹嗪酮偶联分子的应用
CN109529045B (zh) * 2019-01-08 2021-05-18 丹诺医药(苏州）有限公司 利福霉素-喹嗪酮偶联分子及其药学上可接受的盐的应用
CN109464673A (zh) * 2019-01-08 2019-03-15 丹诺医药(苏州）有限公司 利福霉素-喹嗪酮偶联分子及其盐的应用和制剂
CN109942474B (zh) * 2019-03-04 2020-09-18 华中科技大学 一种邻叠氮-肼类化合物及其制备方法
CN115501230B (zh) * 2022-08-05 2023-11-21 丹诺医药(苏州）有限公司 利福霉素-喹嗪酮偶联分子软膏剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1293503C (en) * 1988-03-18 1991-12-24 Fumihiko Kanoo Substituted benzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
US5786350A (en) 1993-05-24 1998-07-28 Gruppo Lepetit S.P.A. 36-derivatives of rifamycins and their use as antimicrobial agents
WO2003045319A2 (en) * 2001-11-21 2003-06-05 Activbiotics, Inc. Targeted therapeutics and uses thereof
WO2005070940A2 (en) * 2004-01-13 2005-08-04 Cumbre Pharmaceuticals Inc. Rifamycin derivatives effective against drug-resistant microbes
EP1723150A1 (de) 2004-01-13 2006-11-22 Cumbre Pharmaceuticals Inc. Gegen arzneimittel resistente mikrobenwirksame rifamyciniminoderivate

Also Published As

Publication number Publication date
WO2006012443A1 (en) 2006-02-02
WO2006012470A1 (en) 2006-02-02
US7229996B2 (en) 2007-06-12
US20060019985A1 (en) 2006-01-26
CN101031572B (zh) 2010-12-08
HK1102808A1 (en) 2007-12-07
CN101031572A (zh) 2007-09-05
JP2008507548A (ja) 2008-03-13
JP5236944B2 (ja) 2013-07-17
EP1768987A1 (de) 2007-04-04
AU2005267054A1 (en) 2006-02-02
JP2008507549A (ja) 2008-03-13
CA2574307A1 (en) 2006-02-02
EP1781670A1 (de) 2007-05-09
NZ565002A (en) 2009-08-28
CA2574301A1 (en) 2006-02-02
US7226931B2 (en) 2007-06-05
ATE427311T1 (de) 2009-04-15
JP5153329B2 (ja) 2013-02-27
CA2574301C (en) 2013-09-10
AU2005267054B2 (en) 2011-06-23
CN101065385A (zh) 2007-10-31
US20060019986A1 (en) 2006-01-26
EP1768987B1 (de) 2009-04-01

Similar Documents

Publication Publication Date Title
ATE427311T1 (de) (r/s) rifamycin-derivate, ihre herstellung und pharmazeutische zusammensetzungen
IL204621A (en) Amino Acid Derivatives - γ - In bicycles preparations containing them and their uses
EP2266623A3 (de) Prodrugs mit neuen biospaltbaren Verbindern
WO2008108386A1 (ja) 医薬組成物
HUP0401729A2 (hu) IV típusú foszfodiészteráz inhibitor hatású alkin-aril-naftiridin-4(1H)-on-származékok és ezeket tartalmazó gyógyszerkészítmények
TW200628161A (en) Novel betulin derivatives, preparation thereof and use thereof
DE60144392D1 (de) Antivirale mittel
AU2003222106A1 (en) Thiopene-based tricyclic compounds and pharmaceutical compositions comprising same
WO2010032147A3 (en) Hydroxamic acid derivatives useful as antibacterial agents
WO2003010135A1 (fr) Nouveaux derives de l'acide phenylpropionique
GB0007405D0 (en) Compounds
EP1813270A4 (de) Proteininhibitoren der hsp90-familie
BRPI0408240A (pt) composto, utilização de um composto e composição farmacêutica
DE60044369D1 (de) Synthetisches oligomannosid, seine herstellung und verwendung
MY140325A (en) Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them
MY141472A (en) Substituted phenyl phenol leukotriene antagonists
WO2007080270A3 (fr) Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation
WO2002020525A3 (en) Protein tyrosine phosphatase inhibitor
TW200745153A (en) Trehalose compound and pharmaceutical comprising the compound
NO20060277L (no) Anvendelse av bisyklo [2.2.1] heptanderivater til fremstilling av nevrobeskyttende farmasoytiske sammensetninger
SG158899A1 (en) Peptidic compounds
TR200200550T2 (tr) Piruvat dehidrojenaz aktivitesini yükselten ikameli n-fenil 2-hidroksi -2- metil -3,3,3- triflüoropropanamid türevleri.
BRPI0416708A (pt) derivados de aminoquinazolidinadiona antibacterianos
AU2003294031A1 (en) Dust-free pigment compositions obtainable by spray-drying
RS20050837A (en) NEW 3-DECLADINOSYL 9a-N-CARBAMOYL AND 9a-N-THIOCARBAMOYL DERIVATIVES OF 9-DEOX-9-DIHYDRO-9a-AZA-9A- HOMOERYTHROMYCIN A NEW 3- DECLADINOSYL 9A-N-CARBAMOYL AND -A- N-THIOCARBAMOYL DERIVATIVES OF 9- DEOX-9-DIHYDRO-9A-AZA-9A- HOMOERYTHROMYCIN A

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: CUMBRE IP VENTURES L.P., DALLAS, TEX., US

8364 No opposition during term of opposition